Lv5
1440 积分 2025-08-11 加入
Cadonilimab: First Approval
8天前
已完结
Adjuvant Chemoradiation and Immunotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Cancer
19天前
已完结
Adjuvant Chemoradiation and Immunotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Cancer
19天前
已完结
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
27天前
已完结
Icaritin promotes tumor T‐cell infiltration and induces antitumor immunity in mice
27天前
已完结
Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study
1个月前
已完结
On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial
1个月前
已完结
Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma
1个月前
已完结
Real-world 10-year retrospective study of the guidelines for diagnosis and treatment of primary liver cancer in China
1个月前
已完结
ESMO adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours
1个月前
已完结
皖公网安备34019202002308
